Zacks Investment Research cut shares of LivaNova (NASDAQ:LIVN) from a buy rating to a hold rating in a research report sent to investors on Thursday morning.

According to Zacks, “LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company’s operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. “

LIVN has been the topic of several other research reports. BidaskClub cut shares of LivaNova from a strong-buy rating to a buy rating in a research report on Tuesday, September 18th. Stifel Nicolaus boosted their price target on shares of LivaNova from $135.00 to $140.00 and gave the stock a buy rating in a research report on Monday, September 17th. Needham & Company LLC restated a buy rating and issued a $128.00 price target on shares of LivaNova in a research report on Wednesday, July 18th. Finally, ValuEngine upgraded shares of LivaNova from a buy rating to a strong-buy rating in a research report on Wednesday, June 27th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Buy and a consensus price target of $103.50.

LIVN stock opened at $122.32 on Thursday. LivaNova has a one year low of $68.24 and a one year high of $131.54. The company has a current ratio of 1.51, a quick ratio of 1.08 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $5.94 billion, a PE ratio of 35.46, a P/E/G ratio of 3.58 and a beta of 0.93.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, August 1st. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.04. LivaNova had a negative net margin of 4.93% and a positive return on equity of 9.24%. The company had revenue of $287.50 million for the quarter, compared to analysts’ expectations of $278.08 million. During the same quarter in the previous year, the business posted $0.93 earnings per share. LivaNova’s quarterly revenue was up 12.4% on a year-over-year basis. equities research analysts predict that LivaNova will post 3.18 EPS for the current year.

In other LivaNova news, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction on Monday, July 16th. The shares were sold at an average price of $102.19, for a total transaction of $102,190.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Douglas John Manko sold 2,058 shares of the business’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $121.61, for a total transaction of $250,273.38. The disclosure for this sale can be found here. Insiders sold 8,058 shares of company stock worth $935,738 in the last 90 days. 0.41% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of LIVN. Wells Fargo & Company MN increased its position in LivaNova by 149.9% during the first quarter. Wells Fargo & Company MN now owns 895,623 shares of the company’s stock valued at $79,263,000 after acquiring an additional 537,282 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in LivaNova by 18.9% during the first quarter. State Board of Administration of Florida Retirement System now owns 23,709 shares of the company’s stock valued at $2,098,000 after acquiring an additional 3,770 shares during the last quarter. Swiss National Bank increased its position in LivaNova by 3.5% during the first quarter. Swiss National Bank now owns 71,419 shares of the company’s stock valued at $6,321,000 after acquiring an additional 2,400 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in LivaNova by 8.1% during the first quarter. Schwab Charles Investment Management Inc. now owns 273,855 shares of the company’s stock valued at $24,237,000 after acquiring an additional 20,419 shares during the last quarter. Finally, Aperio Group LLC increased its position in LivaNova by 69.2% during the first quarter. Aperio Group LLC now owns 11,523 shares of the company’s stock valued at $1,020,000 after acquiring an additional 4,713 shares during the last quarter. Institutional investors and hedge funds own 86.92% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Recommended Story: Return on Equity (ROE)

Get a free copy of the Zacks research report on LivaNova (LIVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.